James Colasacco, MD
Cardiology · Amityville, NYNPI 1568411353
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 325 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations.
Across 325 payments — averaging $23.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Novartis$897
- Abbott$728
- Actelion Pharmaceuticals US, Inc.$643
- Boston Scientific$379
- E.r. Squibb & Sons, L.L.C.$313
- plus $4K from 29 others
What the payments were for
- Food & beverage$7,517100%
- Education$310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 57 | $1,021 |
| Novartis | 50 | $897 |
| Abbott | 11 | $728 |
| Actelion Pharmaceuticals US, Inc. | 31 | $643 |
| Boston Scientific | 15 | $379 |
| E.r. Squibb & Sons, L.L.C. | 13 | $313 |
| Merck | 11 | $311 |
| Amgen | 12 | $305 |
| Novo Nordisk | 15 | $304 |
| Pfizer | 16 | $280 |
| AstraZeneca | 8 | $228 |
| Medtronic(2 entities) | 4 | $215 |
| Esperion Therapeutics, Inc. | 10 | $213 |
| Bayer | 10 | $211 |
| Daiichi Sankyo Inc. | 8 | $174 |
| Intra-sana Laboratories | 1 | $147 |
| Sanofi-aventis U.S. LLC | 6 | $136 |
| Edwards Lifesciences | 5 | $133 |
| Abiomed | 1 | $130 |
| Lundbeck LLC | 8 | $125 |
| Boehringer Ingelheim | 5 | $122 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $83 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $67 |
| Heartflow, Inc. | 3 | $63 |
| Gilead | 4 | $51 |
| Althera Pharmaceuticals LLC | 2 | $39 |
| Cvrx, Inc. | 1 | $38 |
| Kowa Pharmaceuticals America, Inc. | 3 | $38 |
| Arbor Pharmaceuticals, Inc. | 2 | $37 |
| Baxter Healthcare | 1 | $28 |
| Currax Pharmaceuticals LLC | 1 | $25 |
| Irhythm Technologies, Inc. | 1 | $25 |
| GSK | 1 | $19 |
| Dexcom, Inc. | 1 | $15 |
| Bardy Diagnostics, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$220
- CARDIOMEMS$173
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$165
- MitraClip System$164
- AURORA EV-ICD MRI SURESCAN$150
- Reltone 200 Mg$147
- GLYCATE$147
- Reltone 400 Mg$147
- WATCHMAN FLX$130
- FARXIGA$120
- Allure CRT Pacemaker$113
How this compares
$7,548 in reported general payments places this provider in the 80th percentile of 112 cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 164 | $201,685 |
| EliquisApixaban | 188 | $197,296 |
| EntrestoSacubitril/Valsartan | 41 | $49,129 |
| BrilintaTicagrelor | 31 | $23,150 |
| MultaqDronedarone Hcl | 18 | $16,600 |
| Ranolazine ErRanolazine | 147 | $16,169 |
| OzempicSemaglutide | 12 | $11,245 |
| Repatha SureclickEvolocumab | 12 | $9,704 |
| Nebivolol Hcl | 85 | $7,042 |
| Metoprolol Succinate | 326 | $5,504 |
| Atorvastatin Calcium | 319 | $3,657 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 15 | $3,339 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 91 | $2,694 |
| Losartan Potassium | 237 | $2,570 |
| Rosuvastatin Calcium | 154 | $2,161 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $1,021 | $201,685164 claims |
| PfizerEliquis | $280 | $197,296188 claims |
| NovartisEntresto | $897 | $49,12941 claims |
| AstraZenecaBrilinta | $228 | $23,15031 claims |
| Sanofi-aventis U.S. LLCMultaq | $136 | $16,60018 claims |
| Novo NordiskOzempic | $304 | $11,24512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 112 cardiology providers in New York.
Other cardiology in Amityville
- Bimalkumar BrahmbhattAmityville$31K
- Ralph CaselnovaAmityville$16K
- Felix OviasuGarden City$150K
- David D'agateSmithtown$69K
- Michael SiegalNew York$43K
- Michael AvaricioOzone Park$41K
- Michael HappesSmithtown$30K
- Meyer AbittanRoslyn$28K
- Perminder GrewalStony Point$19K
- Paul SapiaRoslyn$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.